Group 1: Momentum Investing Overview - Momentum investing involves following a stock's recent trend, with the aim of buying high and selling higher, capitalizing on established price movements [1] - The Zacks Momentum Style Score helps define momentum characteristics, with United Therapeutics (UTHR) currently holding a Momentum Style Score of B [2] - Style Scores complement the Zacks Rank system, which has a strong track record of outperforming the market, with UTHR rated as 1 (Strong Buy) [3] Group 2: Performance Metrics of United Therapeutics - UTHR shares have increased by 2.75% over the past week, outperforming the Zacks Medical - Drugs industry, which rose by 1.76% [5] - Over the last quarter, UTHR shares have risen by 23.21%, and over the past year, they have gained 41.37%, compared to the S&P 500's increases of 8.91% and 20.56% respectively [6] - The average 20-day trading volume for UTHR is 480,853 shares, indicating a bullish sign if the stock is rising with above-average volume [7] Group 3: Earnings Outlook - In the past two months, 5 earnings estimates for UTHR have been revised upwards, raising the consensus estimate from $24.48 to $25.59 [9] - For the next fiscal year, 7 estimates have also moved higher, with no downward revisions during the same period [9] - These positive trends contribute to UTHR's status as a 1 (Strong Buy) stock with a Momentum Score of B, making it a potential pick for near-term gains [9]

Investors with an interest in Medical - Drugs stocks have likely encountered both United Therapeutics (UTHR) and Zoetis (ZTS) . But which of these two stocks presents investors with the better value opportunity right now? Let's take a closer look. The best way to find great value stocks is to pair a strong Zacks Rank with an impressive grade in the Value category of our Style Scores system. The Zacks Rank is a proven strategy that targets companies with positive earnings estimate revision trends, while our ...

United Therapeutics Corporation Second Quarter 2024 Corporate Update July 31, 2024 2 INTRODUCTION Safe Harbor Statement All statements in this presentation are made as of July 31, 2024. We undertake no obligation to publicly update or revise these statements, whether as a result of new information, future events or otherwise. Statements included in this presentation that are not historical in nature are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. ...

United Therapeutics Corporation (NASDAQ:UTHR) Q2 2024 Earnings Conference Call July 31, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson & Chief Executive Officer Michael Benkowitz - President & Chief Operating Officer James Edgemond - Chief Financial Officer & Treasurer Leigh Peterson - Executive Vice President-Product Development & Xenotransplantation Conference Call Participants Roanna Ruiz - Leerink Partners Jessica Fye - JPMorgan Ash Verma ...

United Therapeutics (UTHR) came out with quarterly earnings of $5.85 per share, missing the Zacks Consensus Estimate of $6.33 per share. This compares to earnings of $5.24 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -7.58%. A quarter ago, it was expected that this drugmaker would post earnings of $5.63 per share when it actually produced earnings of $6.17, delivering a surprise of 9.59%. Over the last four quarters, the c ...

Exhibit 99.1 SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., July 31, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended June 30, 2024. Total revenues in the second quarter of 2024 grew 20 percent year-over-year to $714.9 million, compared to $596.5 million in the second quarter of 2023. Key financial highlights include (dollars in millions, except per share data): United Therapeutics Corporation Reports Second ...

Part I. Financial Information | --- | --- | --- | --- | --- | |-------------------------------------|-------|----------------------------|-----------------------------|----------------------| | Due within one year | $ | Amortized Cost \n 1,632.2 | As of June 30, 2024 \n \n$ | Fair Value \n1,622.1 | | Due in one to three years | | 1,337.2 | | 1,330.4 | | Total | $ | 2,969.4 | $ | 2,952.5 | As of June 30, 2024 and December 31, 2023, we maintained non-controlling equity investments in privately-held companies ...

Core Insights - The article emphasizes the importance of combining a strong Zacks Rank with a high Value grade to identify great value stocks [1] - It highlights traditional metrics that value investors use to find undervalued stocks [2] Company Comparisons - United Therapeutics (UTHR) has a forward P/E ratio of 13.21 and a PEG ratio of 1.43, indicating a favorable valuation compared to Catalent (CTLT), which has a forward P/E of 49.28 and a PEG ratio of 1.69 [3][4] - UTHR's P/B ratio is 2.73, while CTLT's P/B ratio is 2.90, further supporting UTHR's superior valuation metrics [6] - UTHR is rated with a Zacks Rank of 2 (Buy), while CTLT has a Zacks Rank of 5 (Strong Sell), indicating a better earnings outlook for UTHR [8] Valuation Metrics - The article discusses various key metrics used in the Value category, including P/E ratio, P/S ratio, earnings yield, and cash flow per share, which are essential for identifying undervalued companies [9]

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both. It also includes access to the Zacks Style Scores. The Zacks Style Scores is a unique set of guidelines that rates stocks based on three popular investing types, and were developed as complementary indicators for the Zacks Rank. This combination helps investors choose securities with the highest ...

Core Viewpoint - The analysis suggests that United Therapeutics (UTHR) is currently a more attractive investment option compared to Catalent (CTLT) for value investors, based on Zacks Rank and various valuation metrics [2][3][6]. Group 1: Zacks Rank and Earnings Outlook - UTHR has a Zacks Rank of 2 (Buy), indicating a positive earnings estimate revision trend, while CTLT has a Zacks Rank of 5 (Strong Sell), suggesting a negative outlook [3]. - The emphasis on positive earnings estimate revisions indicates that UTHR is likely experiencing an improvement in its earnings outlook compared to CTLT [3]. Group 2: Valuation Metrics - UTHR has a forward P/E ratio of 13.17, significantly lower than CTLT's forward P/E of 49.27, indicating that UTHR may be undervalued relative to CTLT [8]. - UTHR's PEG ratio is 1.43, while CTLT's PEG ratio is 1.69, suggesting that UTHR offers better value when considering expected earnings growth [8]. - UTHR has a P/B ratio of 2.72, compared to CTLT's P/B of 2.90, further supporting the notion that UTHR is a more attractive investment [5]. Group 3: Value Grades - UTHR has received a Value grade of B, while CTLT has a Value grade of D, indicating that UTHR is viewed as a better value investment based on key financial metrics [9].